Publication:
The Safety of Dupilumab in Clinical Practice: 52 Weeks of Experience at 5 Referral Hospitals in Andalusia.

Simple item page
dc.contributor.authorRuiz-Villaverde, R
dc.contributor.authorArmario-Hita, J C
dc.contributor.authorDominguez-Cruz, J
dc.contributor.authorPereyra-Rodriguez, Jose Juan
dc.date.accessioned2023-02-09T09:35:35Z
dc.date.available2023-02-09T09:35:35Z
dc.date.issued2020-06-09
dc.identifier.doi10.1016/j.ad.2019.05.007
dc.identifier.essn2173-5778
dc.identifier.pmid32531242
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.ad.2019.05.007
dc.identifier.urihttp://hdl.handle.net/10668/15728
dc.issue.number8
dc.journal.titleActas dermo-sifiliograficas
dc.journal.titleabbreviationActas Dermosifiliogr (Engl Ed)
dc.language.isoen
dc.language.isoes
dc.organizationIBIS
dc.page.number699-700
dc.pubmedtypeCase Reports
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshDermatitis, Atopic
dc.subject.meshHospitals
dc.subject.meshHumans
dc.subject.meshReferral and Consultation
dc.titleThe Safety of Dupilumab in Clinical Practice: 52 Weeks of Experience at 5 Referral Hospitals in Andalusia.
dc.title.alternativeAnálisis de seguridad de dupilumab en práctica clínica real. Experiencia a 52 semanas de cinco centros de referencia en Andalucía.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number111
dspace.entity.typePublication

Files

Collections

Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía